Selpercatinib, another RET selective receptor tyrosine kinase inhibitor was investigated in the phase I/II basket trial (LIBRETTO-001).236 Of the 41 patients, ORR was 43.9% (95% CI 28.5–60.3), two patients had CCA and achieved partial responses.236. The gene discussed is RET; the disease is cholangiocarcinoma.